# Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

> **NCT06109779** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 757 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Rilvegostomig
- **DRUG:** Placebo
- **DRUG:** Capecitabine
- **DRUG:** Gemcitabine/Cisplatin
- **DRUG:** S-1 [Tegafur/Oteracil/gimeracil]

## Key facts

- **NCT ID:** NCT06109779
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-04
- **Primary completion:** 2029-01-02
- **Final completion:** 2030-05-03
- **Target enrollment:** 757 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06109779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06109779, "Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06109779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*